CR6706A - PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS - Google Patents

PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS

Info

Publication number
CR6706A
CR6706A CR6706A CR6706A CR6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A
Authority
CR
Costa Rica
Prior art keywords
compounds
substituted
unsubstituted
pirido
diamins
Prior art date
Application number
CR6706A
Other languages
Spanish (es)
Inventor
Myra Dobrusin Ellen
Prasad Venkata Nagendra Josyula Vara
John Booth Richard
Joseph Mcnamara Dennis
Laurence Toogood Peter
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6706A publication Critical patent/CR6706A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Consiste en compuestos de formula en la cual R2, R7, R13, y R15, son independientemente, hidrogeno o alquilo inferior sustituido o sin sustituir, alquenilo inferior sustituido o sin sustituir, alquinilo inferior sustituido o sin sustituir, o bien -(CH2) nR112 sustituido o sin sustituir y otros compuestos. Estos compuestos y sus composiciones farmaceuticas son utiles para tratar trastornos proliferativos celulares, tales como cancer y restenosis. Estos compuestos son potentes inhibidores de cdks y de cinasas mediadas por factor de crecimiento.It consists of compounds of formula in which R2, R7, R13, and R15, are independently substituted or unsubstituted hydrogen or lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, or - (CH2) nR112 substituted or unsubstituted and other compounds. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.

CR6706A 2000-01-25 2002-07-17 PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS CR6706A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
CR6706A true CR6706A (en) 2005-04-04

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6706A CR6706A (en) 2000-01-25 2002-07-17 PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS

Country Status (34)

Country Link
EP (1) EP1254137A1 (en)
JP (1) JP4047010B2 (en)
KR (1) KR20020065939A (en)
CN (1) CN1395578A (en)
AP (1) AP2002002586A0 (en)
AR (1) AR030044A1 (en)
AU (1) AU2542501A (en)
BG (1) BG106850A (en)
BR (1) BR0107751A (en)
CA (1) CA2397961C (en)
CO (1) CO5261549A1 (en)
CR (1) CR6706A (en)
CZ (1) CZ20022475A3 (en)
DZ (1) DZ3266A1 (en)
EA (1) EA200200643A1 (en)
EE (1) EE200200405A (en)
GT (1) GT200100016A (en)
HN (1) HN2001000013A (en)
HU (1) HUP0204141A3 (en)
IL (1) IL150545A0 (en)
IS (1) IS6443A (en)
MA (1) MA26868A1 (en)
MX (1) MXPA02007221A (en)
NO (1) NO20023527L (en)
OA (1) OA12161A (en)
PA (1) PA8510701A1 (en)
PE (1) PE20011066A1 (en)
PL (1) PL356802A1 (en)
SK (1) SK10632002A3 (en)
SV (1) SV2002000294A (en)
TN (1) TNSN01014A1 (en)
WO (1) WO2001055147A1 (en)
YU (1) YU50402A (en)
ZA (1) ZA200205879B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
PE20030008A1 (en) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
MXPA04010267A (en) 2002-04-19 2005-02-03 Smithkline Beecham Corp Novel compounds.
KR20050084027A (en) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US7550589B2 (en) * 2004-09-21 2009-06-23 Hoffman-La Roche Inc. 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors
PE20061351A1 (en) 2005-03-25 2007-01-14 Glaxo Group Ltd 8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
AU2006279992A1 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors
FR2910813B1 (en) * 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EA201100879A1 (en) * 2008-12-01 2012-01-30 Мерк Патент Гмбх PYRIDOPYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
EP3733184B1 (en) * 2013-03-14 2023-08-30 Icahn School of Medicine at Mount Sinai Pyrimidine compounds for use in the treatment of cancer
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (en) * 2014-09-02 2016-11-02 한국원자력의학원 Pyrimidine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof
CN107286180B (en) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 Heteropyridopyrimidinone derivatives as CDK inhibitors and their applications
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MX9702245A (en) * 1994-11-14 1997-06-28 Warner Lambert Co 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EE200000706A (en) * 1998-05-26 2002-06-17 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cell proliferation

Also Published As

Publication number Publication date
TNSN01014A1 (en) 2005-11-10
NO20023527L (en) 2002-09-10
PL356802A1 (en) 2004-07-12
CZ20022475A3 (en) 2003-03-12
AP2002002586A0 (en) 2002-09-30
JP2003523357A (en) 2003-08-05
WO2001055147A1 (en) 2001-08-02
EA200200643A1 (en) 2002-12-26
CN1395578A (en) 2003-02-05
EP1254137A1 (en) 2002-11-06
CA2397961C (en) 2008-08-26
YU50402A (en) 2005-11-28
MA26868A1 (en) 2004-12-20
CA2397961A1 (en) 2001-08-02
NO20023527D0 (en) 2002-07-24
OA12161A (en) 2006-05-08
KR20020065939A (en) 2002-08-14
BG106850A (en) 2003-02-28
CO5261549A1 (en) 2003-03-31
DZ3266A1 (en) 2001-08-02
HUP0204141A2 (en) 2003-04-28
GT200100016A (en) 2001-10-19
AU2542501A (en) 2001-08-07
IL150545A0 (en) 2003-02-12
BR0107751A (en) 2002-11-12
IS6443A (en) 2002-06-25
HUP0204141A3 (en) 2005-03-29
SV2002000294A (en) 2002-07-16
SK10632002A3 (en) 2003-06-03
HN2001000013A (en) 2001-06-18
AR030044A1 (en) 2003-08-13
ZA200205879B (en) 2003-09-29
PA8510701A1 (en) 2002-12-11
MXPA02007221A (en) 2002-11-29
EE200200405A (en) 2003-12-15
PE20011066A1 (en) 2001-10-22
JP4047010B2 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
AR030044A1 (en) PIRIDO (2,3-D) PIRIMIDIN-2,7-KINASE INHIBITING DIAMINS
CR6736A (en) 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA
BRPI0507644A (en) pyrazolopyrimidines as cyclin-dependent kinase inhibitors
ES2192877T3 (en) 4-ALQUENIL (AND ALQUINIL) OXINDOLS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES, IN PARTICULAR CDK2.
DK1648905T3 (en) Inhibitors of thienopyridine and furopyridine kinase
CR7899A (en) PROTEIN QUINASA INHIBITING TRICICLIC COMPOUNDS TO IMPROVE THE EFFECTIVENESS OF ANTIENOPLASTIC AGENTS AND DERIVATIVES OF DIAZENPAMDIONILO AS QUINASE INHIBITORS
PE20090058A1 (en) HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS INHIBITORS OF AKT ACTIVITY
TW200407311A (en) N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
YU61402A (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
ECSP078062A (en) 1,4-DIHYDROPIRIDINE-CONDENSED HETEROCICLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM
GEP20125368B (en) Kinase inhibitors
MXPA05011296A (en) Kinase inhibitor phosphonate conjugates.
BRPI0511975A (en) pyrazolopyrimidines
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
TN2009000329A1 (en) 2-AMINO-5,7-DIHYDRO-6H-PYRROLO [3,4-d] -PYRIMIDINE DERIVATIVES AS INHBITORS OF HSP-90 FOR THE TREATMENT OF CANCER
BRPI0606463A2 (en) oxytocin antagonist substituted triazole derivatives
MXPA05009151A (en) Heterocyclic kinase inhibitors.
CR9579A (en) THYROSINE KINASE INHIBITORS
PA8613001A1 (en) TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
AR026037A1 (en) INDOLINONES REPLACED IN POSITION 5, ITS PREPARATION AND ITS USE AS MEDICATIONS
AR056860A1 (en) TRIAZOL DERIVATIVES INHIBITORS OF QUINASA TGF-BETA1 RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR TUMOR TREATMENT
ES2192878T3 (en) 4,5-AZOLO-OXINDOLS.
AU3324201A (en) Tosylproline analogs as thymidylate synthase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)